Abstract:Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Rembrandt Institute for Cardiovascular Sciences Background Venous bypass grafts may have limited patency due to excessive intimal hyperplasia and accelerated atherosclerosis. YAP-TAZ signaling regulates cellular responses to biomechanical cues, such as disturbed flow or vessel distention as seen in vein grafts. YAP activation leads to inflammation and angiogenesis, which both contribute to vein graft atherosclerosis. Inhibition of YAP-TAZ attenuates naive atherogenesis, but its potential to inhibit intraplaque angiogenesis and reduce vein graft atherosclerosis has not been explored. Methods Saphenous vein progenitor cells (SVPs) were subjected to mechanical strain in vitro to assess YAP activation. IHC to assess YAP-expression was performed on vein grafts from pigs as well as ex vivo cultured human saphenous veins. Furthermore, YAP-IHC was performed on murine vein grafts from hypercholesterolemic ApoE3*Leiden mice harvested at early, mid- and late-stage disease timepoints to assess optimal treatment window. In a separate experiment, mice (n=11-13/group) underwent bypass surgery and were treated with the FDA-approved YAP-TAZ inhibitor Verteporfin (50 mg/kg) or vehicle 3 times/week from day 10 until sacrifice (day 28). Ultrasound was used to longitudinally quantify vascular remodeling. Vein grafts were harvested and processed for morphometric and compositional analysis. Results Mechanical strain induced activation of YAP and its downstream targets (Ctgf, Cyr61) in SVPs, which was inhibited by Verteporfin (confirmed by WB, IP and qPCR). Moreover, YAP was abundantly expressed in pig vein graft lesions, whilst Verteporfin blocked YAP expression in ex vivo cultured human saphenous veins after exposure to disturbed flow. In addition, YAP was increasingly expressed during vein graft lesion development in mice, reaching its peak around day 14, which coincides with the initiation of intraplaque angiogenesis. Furthermore, YAP was predominantly expressed in luminal and adventitial endothelial cells. Analysis of ultrasound demonstrated that Verteporfin prevented vein graft thickening in mice over time. End-point histology revealed that the intima/media ratio was significantly decreased by Verteporfin treatment (37%, p=0.001). Intraplaque angiogenesis was also reduced (34%, p=0.002), whilst neovessel maturation was improved upon verteporfin treatment. The vessel wall ACTA2 content was reduced (42%, p=0.023), whilst collagen was not altered between both groups, indicating that Verteporfin diminished the fibroproliferative response without affecting vessel wall stability. Conclusion Verteporfin inhibited YAP-TAZ activation induced by mechanical strain in vitro (SVPs) as well as ex vivo (cultured human saphenous veins). In vivo, Verteporfin treatment resulted in a significant decrease of vein graft atherosclerosis and intraplaque angiogenesis. Therefore, therapeutic targeting of YAP-TAZ using Verteporfin might be a new candidate to improve vein graft patency.

What problem does this paper attempt to address?

This paper attempts to solve the problem of limited venous graft patency rate after venous grafting due to excessive intimal hyperplasia and accelerated atherosclerosis. Specifically, the paper explores the possibility of preventing venous graft atherosclerosis by inhibiting the YAP - TAZ signaling pathway activated by mechanical stimulation. ### Background Venous bypass grafting may affect its patency rate due to excessive intimal hyperplasia and accelerated atherosclerosis. The YAP - TAZ signaling pathway regulates the cell's response to mechanical stimuli, such as disturbed blood flow or vasodilation, which are common in venous grafts. The activation of YAP can lead to inflammation and neovascularization, both of which promote atherosclerosis in venous grafts. Although it is known that inhibiting YAP - TAZ can attenuate primary atherosclerosis, its potential in inhibiting intra - plaque neovascularization and reducing venous graft atherosclerosis has not been explored. ### Methods 1. **In vitro experiments**: Human saphenous vein progenitor cells (SVPs) were treated with mechanical strain to evaluate the activation of YAP. 2. **Pig and human samples**: YAP expression in pig venous grafts and ex - vivo - cultured human saphenous veins was detected by immunohistochemistry (IHC). 3. **Mouse model**: Venous graft surgery was performed in hypercholesterolemic ApoE3*Leiden mice, and samples were collected at early, intermediate, and late disease time points to evaluate the optimal treatment window. 4. **Drug intervention**: Mice received the FDA - approved YAP - TAZ inhibitor Verteporfin (50 mg/kg) or placebo treatment, three times a week, from day 10 to day 28. Vascular remodeling was quantified longitudinally using ultrasound. Finally, venous graft samples were collected for morphological and compositional analysis. ### Results 1. **In vitro experiments**: Mechanical strain induced the activation of YAP and its downstream target genes (Ctgf, Cyr61) in SVPs, and Verteporfin inhibited this activation (confirmed by WB, IP, and qPCR). 2. **Pig and human samples**: YAP was highly expressed in pig venous graft lesions, and Verteporfin blocked YAP expression in ex - vivo - cultured human saphenous veins exposed to disturbed blood flow. 3. **Mouse model**: YAP gradually increased during the development of mouse venous graft lesions, reaching a peak at about day 14, which was consistent with the onset time of intra - plaque neovascularization. YAP was mainly expressed in the lumen and adventitial endothelial cells. 4. **Drug intervention**: Ultrasound results showed that Verteporfin prevented the thickening of mouse venous grafts over time. Final histological analysis showed that Verteporfin significantly reduced the intima/media ratio (37%, p = 0.001). Intra - plaque neovascularization was also reduced by 34% (p = 0.002), and the neovascular maturity was improved. Verteporfin also reduced the vascular wall ACTA2 content (42%, p = 0.023), but had no effect on collagen, indicating that Verteporfin reduced the fibroproliferative response without affecting vascular wall stability. ### Conclusion Verteporfin inhibits the YAP - TAZ activation induced by mechanical strain in vitro (SVPs) and ex - vivo (cultured human saphenous veins). In vivo experiments, Verteporfin treatment significantly reduces venous graft atherosclerosis and intra - plaque neovascularization. Therefore, targeting YAP - TAZ with Verteporfin may be a new candidate method to improve venous graft patency rate.

Therapeutic inhibition of biomechanically-activated YAP-TAZ signaling prevents vein graft atherosclerosis

AIP1 Prevents Graft Arteriosclerosis by Inhibiting Interferon-γ–Dependent Smooth Muscle Cell Proliferation and Intimal Expansion

Mechanical activation of Hippo/TGFb pathways lead human saphenous vein progenitors toward pro-fibrotic differentiation in aorto-coronary bypass failure

Statin therapy prevents expansive remodeling in venous bypass grafts

Topical Hdl Administration Reduces Vein Graft Atherosclerosis in Apo E Deficient Mice

PFKFB3 gene deletion in endothelial cells inhibits intraplaque angiogenesis and lesion formation in a murine model of venous bypass grafting

Thrombosis And Neointima Formation In Vein Grafts Are Inhibited By Locally Applied Aspirin Through Endothelial Protection

Inhibition of Neointima Hyperplasia of Mouse Vein Grafts by Locally Applied Suramin

Spatial Transcriptomic Profiling of Human Saphenous Vein Exposed to Ex Vivo Arterial Haemodynamics—Implications for Coronary Artery Bypass Graft Patency and Vein Graft Disease

Gene Transfer of A Broad Spectrum Cc-Chemokine Inhibitor Reduces Vein Graft Atherosclerosis in Apolipoprotein E-Knockout Mice

Inhibition of BMP9 and BMP10 signalling by the ALK1-Fc Ligand Trap enhances systemic inflammation and increases vein graft atherosclerosis

Accelerated Atherosclerosis and Calcification in Vein Grafts

Mouse Model of Venous Bypass Graft Arteriosclerosis

Periadventitial human stem cell treatment reduces vein graft intimal thickening in pig vein-into-artery interposition grafts

Local Gene Transfer of Tissue Inhibitor of Metalloproteinase-2 Influences Vein Graft Remodeling in a Mouse Model

Mechanical Activation of Cpla2 Impedes Fatty Acid Β-Oxidation in Vein Grafts.

Bletilla striata Polysaccharide Prevents Restenosis of Vein Graft Through Inhibiting Cell Proliferation in Rat Model

Tropoelastin inhibits intimal hyperplasia of mouse bioresorbable arterial vascular grafts

New Mouse Model of Vein Bypass Graft Atherosclerosis

Adventitial Vessel Growth and Progenitor Cells Activation in an Ex Vivo Culture System Mimicking Human Saphenous Vein Wall Strain after Coronary Artery Bypass Grafting

A novel biodegradable external stent regulates vein graft remodeling via the Hippo-YAP and mTOR signaling pathways